Freedom of information requests

Myelofibrosis treatment

Questions

1. How many patients were treated in the past six months (for any disease) with:
   1. Ruxolitinib
   2. Fedratinib
2. Does your Trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?
3. Please provide the total number of patients treated in the last six months for:
   1. Polycythaemia Vera (ICD10 code D45)
   2. Myelofibrosis (ICD10 code D47.4)
   3. Myelofibrosis (ICD10 code D47.4) patients aged 65 and older
4. Of the patients treated in the past six monthswithRuxolitinib, how many patients had a diagnosis for:
   1. Polycythaemia Vera (ICD10 code D45)
   2. Myelofibrosis (ICD10 code D47.4)
   3. Myelofibrosis – low risk*
   4. Myelofibrosis – intermediate risk I*
   5. Myelofibrosis – intermediate risk II or high risk*

* Risk assessment as based on DIPSS scores, if available

5. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past three years?
   1. Of the patients diagnosed with myelofibrosis in the past three years, how many were treated in the past six months with Hydroxycarbamide?
   2. Of the patients diagnosed with myelofibrosis in the past three years, how many were treated in the past six months with Interferon therapy?
   3. Of the patients diagnosed with myelofibrosis in the past three years, how many have received no active treatment in the past six months?

Response

1. 
   
   1. 31
   2. 0
2. Yes
3.  
   1. 162
   2. 40
   3. 25
4. 
   
   1. 0
   2. 0
   3. 0
   4. 0
   5. 0

* Not available

5. 
   
   1. 4
   2. 0
   3. 0